Thus, the antihypertensive effect via the ACE inhibitory activity of a DPP4 inhibitory peptide is expected to be beneficial for the management of T2D patients with hypertension, as well as for hypertension patients with T2D. The gene discussed is ACE; the disease is type 2 diabetes mellitus.